Literature DB >> 7506116

Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix.

T Kihana1, H Tsuda, S Teshima, K Nomoto, S Tsugane, T Sonoda, S Matsuura, S Hirohashi.   

Abstract

BACKGROUND: The overexpression of c-erbB-2 protein is a prognostic marker in patients with breast cancer. Alteration of the c-erbB-2 oncogene in development of adenocarcinoma of the uterine cervix, an unfavorable gynecologic neoplasm, is unknown.
METHODS: To clarify the role of the c-erbB-2 oncogene in adenocarcinoma of the uterine cervix, formalin-fixed, paraffin-embedded tissue sections from 44 cases of cervical adenocarcinoma were immunohistochemically examined for expression of c-erbB-2 protein and for c-erbB-2 gene amplification in DNA by slot blot-hybridization analysis.
RESULTS: The expression of c-erbB-2 protein was detected in 34 cases (77%). Strong expression on cell membranes was detected in 11 cases (25%). Most cases with strong membrane expression of c-erbB-2 protein also showed amplification of the c-erbB-2 gene by slot blot-hybridization. Expression of the protein on cell membranes was more often seen at clinical Stage II or III (9 of 23 [39%]) than at Stage 0 or 1 (2 of 21 [9%]) (P < 0.05, Fisher's exact test). Expression of the c-erbB-2 protein was also associated with poorer prognosis of patients with cervical adenocarcinoma by comparison of survival curves (P < 0.005) and by the Cox regression model analysis.
CONCLUSIONS: Overexpression of c-erbB-2 protein is associated with amplification of c-erbB-2 gene and frequently occurred in cervical adenocarcinomas of the patients with poor prognoses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7506116     DOI: 10.1002/1097-0142(19940101)73:1<148::aid-cncr2820730125>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications.

Authors:  Anjelica Hodgson; Yutaka Amemiya; Arun Seth; Matthew Cesari; Bojana Djordjevic; Carlos Parra-Herran
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

2.  A Detailed Immunohistochemical Analysis of a Large Series of Cervical and Vaginal Gastric-type Adenocarcinomas.

Authors:  Claire Carleton; Lien Hoang; Shatrughan Sah; Takako Kiyokawa; Yevgeniy S Karamurzin; Karen L Talia; Kay J Park; W Glenn McCluggage
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

Review 3.  HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.

Authors:  Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

4.  Adrenocorticotropin-Producing Pituitary Carcinoma with Expression of c-erbB-2 and High PCNA Index: A Comparative Study with Pituitary Adenomas and Normal Pituitary Tissues.

Authors:  Vania Nose-Alberti; Maria Isabel S. Mesquita; Luciana C. Martin; Marcia J. Kayath
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

5.  Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern.

Authors:  Yukihiko Hiroshima; Yong Zhang; Nan Zhang; Ali Maawy; Sumiyuki Mii; Mako Yamamoto; Fuminari Uehara; Shinji Miwa; Shuya Yano; Takashi Murakami; Masashi Momiyama; Takashi Chishima; Kuniya Tanaka; Yasushi Ichikawa; Michael Bouvet; Takuya Murata; Itaru Endo; Robert M Hoffman
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

6.  Tumor-Targeting Salmonella typhimurium A1-R in Combination with Trastuzumab Eradicates HER-2-Positive Cervical Cancer Cells in Patient-Derived Mouse Models.

Authors:  Yukihiko Hiroshima; Yong Zhang; Ming Zhao; Nan Zhang; Takashi Murakami; Ali Maawy; Sumiyuki Mii; Fuminari Uehara; Mako Yamamoto; Shinji Miwa; Shuya Yano; Masashi Momiyama; Ryutaro Mori; Ryusei Matsuyama; Takashi Chishima; Kuniya Tanaka; Yasushi Ichikawa; Michael Bouvet; Itaru Endo; Robert M Hoffman
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

7.  HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.

Authors:  Olga Martinho; Renato Silva-Oliveira; Fernanda P Cury; Ana Martins Barbosa; Sara Granja; Adriane Feijó Evangelista; Fábio Marques; Vera Miranda-Gonçalves; Diana Cardoso-Carneiro; Flávia E de Paula; Maicon Zanon; Cristovam Scapulatempo-Neto; Marise A R Moreira; Fátima Baltazar; Adhemar Longatto-Filho; Rui Manuel Reis
Journal:  Theranostics       Date:  2017-01-15       Impact factor: 11.556

8.  HER2 expression in cervical cancer as a potential therapeutic target.

Authors:  Alma Chavez-Blanco; Victor Perez-Sanchez; Aurora Gonzalez-Fierro; Teresa Vela-Chavez; Myrna Candelaria; Lucely Cetina; Silvia Vidal; Alfonso Dueñas-Gonzalez
Journal:  BMC Cancer       Date:  2004-09-01       Impact factor: 4.430

9.  Prognostic significance of the co-expression of EGFR and HER2 in adenocarcinoma of the uterine cervix.

Authors:  Asako Ueda; Akira Takasawa; Taishi Akimoto; Kumi Takasawa; Tomoyuki Aoyama; Yoshihiko Ino; Masanori Nojima; Yusuke Ono; Masaki Murata; Makoto Osanai; Tadashi Hasegawa; Tsuyoshi Saito; Norimasa Sawada
Journal:  PLoS One       Date:  2017-08-31       Impact factor: 3.240

10.  Prognostic value of p53 protein accumulation in cancer cell nuclei in adenocarcinoma of the uterine cervix.

Authors:  H Tsuda; K Jiko; S Tsugane; M Yajima; T Yamada; K Tanemura; R Tsunematsu; K Ohmi; T Sonoda; S Hirohashi
Journal:  Jpn J Cancer Res       Date:  1995-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.